Viyash Scientific posts record quarter, sets ₹800 cr EBITDA run-rate for FY27
Q4 revenue hit ₹920 crore and EBITDA jumped 64% to ₹200 crore. Management now sees the full-year EBITDA run-rate approaching ₹800 crore.
— 3 earlier stories on Viyash Scientific Ltd. →What's new
- Q4 FY26 revenue rose 19% to ₹920 crore; EBITDA surged 64% to ₹200 crore.
- Management says the full-year FY27 EBITDA run-rate is approaching ₹800 crore.
- Company is evaluating selective inorganic opportunities to strengthen its platform.
Why this matters
The record quarter and an ₹800 crore run-rate indicate a step-change in profitability. Management’s confidence in hitting ₹1,000 crore EBITDA within two to three years hinges on scaling two specific bets: companion animal health and CDMO services. The mention of inorganic moves suggests acquisitions could be the accelerant.
What we're watching
- Execution on the companion animal health and CDMO expansion plans.
- Any announced inorganic deals and their valuation.
- Whether the FY27 EBITDA run-rate translates into full-year delivery.
The full read
Viyash Scientific delivered its best quarter ever in Q4 FY26. Revenue rose 19% to ₹920 crore, and EBITDA jumped 64% to ₹200 crore on stronger formulation sales and better gross margins. That performance has management pointing to a full-year FY27 EBITDA run-rate of ₹800 crore, with a reiterated goal of ₹1,000 crore within two to three years. The two growth bets backing that target are companion animal health and CDMO. The new variable is inorganic growth. Management said it is actively evaluating selective acquisitions to strengthen the platform. The transcript confirms the financial beat but the real update is the roadmap and the appetite for deals.
Questions answered
- How did Viyash Scientific perform in Q4 FY26?
- Viyash posted its strongest-ever quarter with revenue up 19% year-on-year to ₹920 crore. EBITDA jumped 64% to ₹200 crore, driven by formulation sales and improved gross margins.
- What is management's guidance for FY27?
- Management indicated the full-year FY27 EBITDA run-rate is approaching ₹800 crore. They reiterated a longer-term confidence in reaching ₹1,000 crore EBITDA within two to three years.
- What are the key growth levers for the company?
- The two main growth drivers are expansion into the companion animal health business and the CDMO (contract development and manufacturing) pipeline. Management also flagged it is evaluating selective inorganic opportunities.
- What does the mention of inorganic opportunities mean?
- It signals Viyash is considering acquisitions to accelerate its growth strategy and strengthen its business platform. The filing provides no specifics on target size or timeline.
Story so far
All notes on VIYASH →- 22 May 2026 · 10:36 AM IST Viyash Scientific posts record quarter, sets ₹800 cr EBITDA run-rate for FY27
- today Viyash's Italian pet-care bid jumps 28% to ₹188 cr
- today Viyash buys Italian vet distributor for €17M
- 18d ago Viyash Scientific targets ₹1,000 cr EBITDA in 2-3 years, pivots to companion animals